Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2344-2351

  Lagas, Jurjen S ^a   Van Waterschoot, Robert A B ^a   Van Tilburg, Vicky A C J ^a   Hillebrand, Michel J ^b   Lankheet, Nienke ^b   Rosing, Hilde ^b   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; DASATINIB; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM LEUKEMIA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; WILD TYPE;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BRAIN; CELL LINE; DOGS; MICE; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TETRAHYDROISOQUINOLINES; THIAZOLES;

EID: 65249151331     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2253     Document Type: Article

References (44)

1. Borst P, Oude Elferink RP. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
2. O'BrienSG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
4. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99: 1928-37.
5. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002;2:99-102.
6. McCormick F. New-age drug meets resistance. Nature 2001;412:281-2.
7. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
8. Sleijfer S, Wiemer E, Seynaeve C,Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007;12:719-26.
9. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9: 625-32.
10. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydrox- yethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylami- no)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
11. O'HareT, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS- 354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65: 4500-5.
12. Shah NP,Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
13. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytoge- netic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303-9.
14. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerantchron- ic myeloid leukemia in blast crisis. Blood 2007;109: 3207-13.
15. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50.
16. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line ima- tinib: a randomized phase 2 trial. Blood 2007;109: 5143-50.
17. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309-15.
18. Hamada A, Miyano H,Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003;307:824-8.
19. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2.
20. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topo- tecan and SN-38 in vitro.CancerRes 2004;64: 2333-7.
21. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-82.
22. DaiH,MarbachP,LemaireM,HayesM,Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol ExpTher 2003;304:1085-92.
23. BihorelS,CamenischG,LemaireM,Scherrmann JM. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the trans- port of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 2007;102: 1749-57.
24. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007;24:1720-8.
25. Mahon FX, Belloc F, LagardeV, et al. MDR1 gene overexpression confers resistance to imatinib mesy- late in leukemia cell line models. Blood 2003;101: 2368-73.
26. Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108: 678-84.
27. Oostendorp RL, Buckle T, Beijnen JH, van Tellin- gen O, Schellens JH. The effect of P-gp (Mdr1a/ 1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009; 27:31-40.
28. Pfeifer H,Wassmann B, HofmannWK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9:4674 - 81.
29. Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004; 45:695-8.
30. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112: 1005-12.
31. Deguchi Y,Kimura S,AshiharaE, et al. Comparison ofimatinib, dasatinib, nilotinib and INNO-406 inimati- nib-resistant cell lines. Leuk Res 2008;32:980-3.
32. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14:3881 -8.
33. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib resistant chronic myeloid leukaemia. Blood 2008;112: 3348-54.
34. Evers R, Kool M, van Deemter L, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998;101:1310-9.
35. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002;99: 15649-54.
36. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
37. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. IntJ Cancer 2005;116: 824-9.
38. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A1997;94:4028-33.
39. Jonker JW, Freeman J, Bolscher E, et al. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005;23: 1059-65.
40. Goh LB, Spears KJ,Yao D, et al. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 2002;64:1569-78.
41. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemo- ther Pharmacol 2008;61:365-76.
42. Takayama N, Sato N, O'Brien SG, IkedaY, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119:106-8.
43. Bornhauser M, Jenke A, Freiberg-RichterJ, et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesy- late and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004;83:401 -2.
44. Slevin ML,Piall EM,AherneGW, Johnston A,Lister TA. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 1982;10 Suppl 1:157-68.